CEL-SCI Corporation (NYSE: CVM) announced that it has priced its public offering of common stock and warrants. CEL-SCI announced that it has agreed to sell 34,024,000 shares of common stock and warrants to purchase common stock at a price of $0.125.
The FDA has notified CEL-SCI (NYSEMKT:CVM) that its Phase 3 clinical trial assessing Multikine (Leukocyte Interleukin, Injection) for the treatment of head and neck cancer is on full clinical hold, meaning that all dosing must cease immediately.
CEL-SCI Corp. has received the official minutes from its Type A (face-to-face) meeting with the U.S. Food and Drug Administration (FDA) concerning the partial clinical hold placed on a Phase 3 trial assessing Multikine (leukocyte interleukin, injection ...
Monitoring the numbers for Cel-Sci Corp (CVM), we are noting that the KAMA is trending up over the last five days. Tracking this reading, traders might be on the lookout for positive near-term momentum.